Nuvo's Revamped Strategy Should Unlock Significant Value
Jason Napodano, CFA - at Seeking Alpha - Wed May 27, 8:41AM CDT
HZNP: 35.94 (+1.13)
Nuvo Research: Buy The Cash And Get The Company For Free
JMY Investments - at Seeking Alpha - Tue May 05, 10:32AM CDT
Is There Any Potential Left In Horizon Pharma Stock?
Max Grigoryev - at Seeking Alpha - Fri Mar 20, 1:55PM CDT
JNJ: 99.53 (+1.13), ACT: 298.98 (-2.94), PFE: 34.36 (+0.50), AZN: 66.45 (+1.90), HZNP: 35.94 (+1.13), MYL: 71.22 (+0.87), TEVA: 61.38 (-0.75)
Nuvo Research Still Worth The Risk
Michael Colavecchia, CFA - Seeking Alpha - Fri Feb 27, 6:46AM CST
Nuvo Research (OTCPK: OTCPK:NRIFF , or NRI on the TSX) reported Q4 and full year results on February 19th, and the investment thesis from my February 10th article remains intact. Here are the key elements to the story, with updates, that each...
Anika Therapeutics files Cingal regulatory apps in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:42PM CST
MNK: 122.44 (+2.18), FLXN: 23.74 (+1.31), XENE: 9.88 (-0.01), HZNP: 35.94 (+1.13), AMPE: 2.51 (+0.24), CBYL: 7.26 (+0.31), ANIK: 33.33 (+0.31)
Nuvo Research May Be Worth The Risk Now
Michael Colavecchia, CFA - Seeking Alpha - Tue Feb 10, 7:36AM CST
I have been following this story for some time, searching for the right entry point. And now is the time. For those of you who are not familiar with the story of Nuvo Research ( OTCPK:NRIFF ), here is a brief summary. The company has a commercial...
Flexion patient dosing underway in lead product study
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:27PM CST
MNK: 122.44 (+2.18), FLXN: 23.74 (+1.31), XENE: 9.88 (-0.01), HZNP: 35.94 (+1.13), AMPE: 2.51 (+0.24), CBYL: 7.26 (+0.31), ANIK: 33.33 (+0.31)
Carbylan Therapeutics on deck for IPO
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 12:13PM CST
MNK: 122.44 (+2.18), FLXN: 23.74 (+1.31), XENE: 9.88 (-0.01), HZNP: 35.94 (+1.13), AMPE: 2.51 (+0.24), ANIK: 33.33 (+0.31), CBYL: 7.26 (+0.31)
Medical Marijuana Goes To Market: Daniel Pearlstein Of M Partners
Life Sciences Report - at Seeking Alpha - Thu Jan 08, 10:42AM CST
Life sciences analyst Daniel Pearlstein of Toronto-based M Partners brings knowledge of the biotech sector and hands-on experience in the startup realm to understanding value and growth in small- and micro-cap life sciences companies. In this...
MNK: 122.44 (+2.18), AUPH: 3.36 (-0.12), HZNP: 35.94 (+1.13), GSK: 42.45 (+0.65), BMY: 69.27 (+1.38)
Update: Horizon Pharma Acquires U.S. Rights For Pennsaid 2%, Long Case Strengthens
ONeil Trader - at Seeking Alpha - Sat Oct 18, 4:30PM CDT
HZNP: 35.94 (+1.13)
Horizon acquires U.S. rights to osteoarthritis drug
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 9:17AM CDT
HZNP: 35.94 (+1.13)